We developed multikinase PIM/PI3K/mTOR inhibitors, and among > 700 cancer cell lines of various origin, neuroblastoma was particularly sensitive toward the triple kinase inhibitor IBL‐302. This evidence concerns the gene PIM1 and neuroblastoma.